JAMA Dermatol

Effectiveness of adalimumab biosimilars for psoriasis on par with that of Humira

March 10, 2025

Amjevita and Imraldi (the latter approved in Europe but not in the U.S.) were as effective as Humira for both new starters and patients switching to biosimilars from Humira.

Study details: This emulation of two targeted pragmatic clinical trials was conducted to compare the effectiveness of adalimumab biosimilars Amjevita and Imraldi with the originator Humira for treating psoriasis. Researchers used data from the British Association of Dermatologists Biologics and Immunomodulators Register, including 11,400 patients from the UK and Ireland. Study outcomes were absolute Psoriasis Area and Severity Index (PASI) score of ≤ 2 and PASI score of ≤4 at 12 months after the index date.

Results: Amjevita and Imraldi new users didn't have a significantly different probability of achieving a PASI score of ≤2 (Amjevita: adjusted odds ratio [aOR], 0.98; 95% confidence interval [CI], 0.78-1.25; Imraldi: aOR, 0.83; 95% CI, 0.64-1.07) and a PASI score of ≤4 (Amjevita: aOR, 1.07; 95% CI, 0.84-1.37; Imraldi: aOR, 0.91; 95% CI, 0.69-1.20) compared with Humira new users.

Patients who switched to Amjevita and Imraldi also had no statistically significant differences in achieving a PASI score of ≤2 (Amjevita: aOR, 1.19; 95% CI, 0.94-1.51; Imraldi: aOR, 0.92; 95% CI, 0.72-1.18) and a PASI score of ≤4 (Amjevita: aOR, 1.32; 95% CI, 0.96-1.84; Imraldi: aOR, 1.00; 95% CI, 0.70-1.41) compared with those who continued Humira.

Source:

Phan DB, et al. (2025, March 5). JAMA Dermatol. Effectiveness of Adalimumab Biosimilars and Originator for Psoriasis. https://pubmed.ncbi.nlm.nih.gov/40042863/